B72.3 antibody

05/01/2007 - "B72.3 shows promise in the differentiation between GIC and benign and malignant ductal epithelium, with no staining supporting benign ductal cells, fine punctate perinuclear staining correlating with GIC, and strong cytoplasmic staining supporting malignancy."
02/01/2011 - "A humanized and CH2 domain-deleted CC49 antibody radiolabeled with (111)In/(90)Y showed improved tumor-to-normal dose ratios over those reported from studies with intact CC49."
02/01/1995 - "The tumors yielded positive results in 23/23, 22/23, 17/23, 22/23, and 18/23 cases when stained with Cam 5.2, AE1/AE3, Leu M-1, CEA, and B72.3, respectively. "
09/01/2005 - "These effects were dose-dependent and under optimized dosing conditions allowed for a 2.45 times increase in the tumor uptake of B72.3 as determined in the biodistribution studies. "
10/01/2015 - "This fluid was subsequently spun many times to obtain sediment for cytology and immunohistochemistry investigation using anti-BerEp-4, CK 7/20, and B72.3. Results of peritoneal cytology were analyzed jointly with clinical factors--patient's age, sex and pathology factors--tumor invasion, involvement of lymph nodes, histological grade, histological type according to Lauren and localization of the cancer in the stomach. "

05/01/1996 - "In a blinded fashion, radiolabeled B72.3 was investigated in operative cases of recurrent colorectal cancer to determine if diagnostic accuracy would be improved to ultimately maximize curability and minimize interventional morbidities. "
06/01/1987 - "Previous studies have demonstrated that radioiodinated B72.3 can selectively bind to human colorectal carcinomas grown in athymic mice. "
04/01/1998 - "Localization of colorectal carcinoma by rhenium-188-labeled B72.3 antibody in xenografted mice."
01/01/1994 - "We conclude that mAb CC49 has better relative uptake in colorectal cancers than mAb B72.3."
01/15/1993 - "We compared the pharmacokinetics, biodistribution, and immune responses of 131I-labeled CC49 and CC83 to 125I-labeled B72.3 by preoperatively coninjecting dual-labeled MAbs into 16 colorectal cancer patients. "

10/15/1993 - "However, the distribution of B72.3 reactivity in adenocarcinomas has not been well-enough defined to determine whether B72.3 immunostaining would be helpful in the diagnosis of adenocarcinoma of unknown origin. "
09/01/1993 - "Future prospective studies comparing CT scans, CEA estimation and B72.3 radioimmunoscintigraphy in a larger group of patients with suspected residual or recurrent colorectal adenocarcinoma may help to define the respective sensitivity and specificity of these techniques."
04/01/1985 - "In this preliminary study, we report that MAb B72.3 may be used as an adjunct for diagnosis of adenocarcinoma in cytological preparations of human effusions. "
05/01/2010 - "B72.3 was positive in 95% of adenocarcinomas and 85% of mucinous lesions. "
07/01/2002 - "Athymic mice xenografted with human colorectal adenocarcinoma LS174T were treated intravenously with low doses (9.25 MBq) of 131I-labeled mAb B72.3 in combination with various intravenous doses of AP. "

07/01/1999 - "BerEP4 and B72.3 appear to be the best markers when both sensitivity and specificity are considered, followed by BG8, while CEA and CA-125 have a limited role in the detection of metastases from gynaecological tumours owing to the low sensitivity of the former and the low specificity of the latter. "
04/01/1995 - "Stromal type for TKH2, B72.3, CA19-9 and CEA were seen in 14 (50%), 13 (46%), 18 (64%) and nine (32%) cases with peritoneal dissemination, respectively, and in four (17%), three (13%), four (17%) and four (17%) cases with liver metastasis, respectively. "
03/01/1993 - "A review of an immunoscintigraphy study of more than 100 women preoperatively staged with 111In-labeled B72.3 (CYT-103) reveals that this technique has a low potential for serious side effects and it can identify miliary spread of ovarian cancer and extra-abdominal metastases. "
04/01/1995 - "The quantitation of In-111 B72.3 uptake (%I.D./g; mean+/-S.D.) was 0.0054+/-0.0021 in breast tumors, 0.0021+/-0.0011 in normal mammary tissue, 0.0053+/-0.0027 in axillary metastasis and 0.0032+/-0.008 in normal axillary nodes. "
07/01/1992 - "The sensitivity of both B72.3 and anti-CEA was greater than 70% either for primary tumors and abdominal recurrences or distant metastases except hepatic ones. "

08/01/1993 - "Improved detection of hepatic lesions using MoAb B72.3 and a modified 111In labelling technique in patients with recurrent colon cancer."
08/01/1993 - "In previous studies with radiolabelled MoAb B72.3, metastatic liver lesions in patients with colon cancer appeared as areas of either increased (hot lesions) or decreased (cold lesions) activity, and extrahepatic lesions appeared as areas of increased activity. "
09/01/1992 - "Twelve patients with metastatic colon cancer were treated with 131I-chimeric B72.3 (IgG-4) at total doses of 28 or 36 mCi/m2 in two or three weekly fractions. "
12/15/1989 - "B72.3 MAb reacted strongly with 21/21 specimens of transitional mucosa and with 17/21 specimens of adjacent colon cancer. "
01/15/1987 - "Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3."